Atopic Dermatitis CD19+ B Cells
Atopic Dermatitis CD19+ B Cells are isolated from IRB-consented donors with clinically confirmed atopic dermatitis. Ideal for investigating IgE class switching, B cell-mediated IgE production, and humoral immune dysregulation in allergic skin disease.
Atopic Dermatitis CD19+ B Cells for Allergy and IgE Research
Atopic Dermatitis CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with atopic dermatitis. These CD19+ B cells reflect disease-associated humoral alterations and are a direct resource for studying IgE class switching, B cell activation, and allergic immunity.
Why B Cells Matter in Atopic Dermatitis
Atopic dermatitis is a chronic inflammatory skin disease driven by epidermal barrier dysfunction and type 2 (Th2) immune skewing — not autoimmunity. B cells sit at a decisive point in that pathway, because they are where IgE actually comes from:
- IgE class switching — IL-4 and IL-13 drive B cells to switch to IgE production, the defining humoral event in atopy and the mechanism upstream of mast cell and basophil sensitisation
- Elevated total and allergen-specific IgE, correlating with disease severity in the extrinsic (allergic) phenotype
- Expanded IgE-committed and memory B cell populations
- Reduced regulatory B cell function — diminished IL-10-producing Bregs, weakening a restraining signal on type 2 inflammation
- Local skin B cell involvement and antigen presentation supporting Th2 responses
- Treatment effects — dupilumab blocks IL-4Rα signalling and measurably reduces IgE over time, so treatment status is essential context
Note that AD divides into extrinsic (IgE-high, allergen-sensitised) and intrinsic (IgE-normal) phenotypes, and these behave differently in B cell studies — worth specifying up front.
Donor Stratification Available
- Total and allergen-specific IgE where tested, with titre values
- Phenotype — extrinsic (IgE-high) vs intrinsic (IgE-normal)
- Disease severity — EASI, SCORAD, or IGA scores where recorded
- Atopic comorbidities — asthma, allergic rhinitis, food allergy
- Treatment status — topical-only, or on dupilumab, JAK inhibitor, or systemic immunosuppressant
- Matched non-atopic controls with low total IgE available
Product Features
- Research Use Only (RUO), CD19+ enriched B cells
- Isolated from clinically diagnosed atopic dermatitis donors
- High viability and enrichment
- Cryopreserved in CryoStor® CS10 media
- Processed within 24 hours of collection
- Flow cytometry purity and viability data per lot
- Ethically sourced with IRB approval and HIPAA compliance
De-identified Donor Data
- Confirmed diagnosis of atopic dermatitis
- Demographics: age, sex assigned at birth, race/ethnicity
- Self-reported clinical history and medication use
Applications
- IgE class switching and germline transcription studies
- B cell phenotyping and function in atopic dermatitis
- IgE production and BCR signalling assays
- Regulatory B cell (Breg) and IL-10 function studies
- BCR repertoire sequencing
- Anti-IgE and IL-4Rα therapeutic mechanism research
- Disease mechanism studies and biomarker identification
- Preclinical immunotherapy development
Other Atopic Dermatitis Specimen Types
Matched material is available as AD CD56+ NK cells, PBMC, serum, plasma, and skin punch biopsy for lesional tissue. Related atopic cohorts include allergy serum and chronic spontaneous urticaria.
Compliance and Quality Assurance
- IRB-approved collection and 21 CFR Part 11-compliant e-consent
- Standardized processing and quality protocols
- HIPAA-compliant data handling
Ordering & Customization
Atopic Dermatitis CD19+ B Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD19+ B cells collection.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
CD19+ B Cells
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
1 Answer
All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more on our PRO surveys and questionnaires page.
Ask a Question
Need a custom CD19+ B Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.